Navigation Links
IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone
Date:3/27/2008

TORONTO, March 27 /PRNewswire/ - IntelliPharmaCeutics Ltd. (Delaware) is pleased to announce significant results from a recently completed pilot clinical trial for its new abuse-resistant, alcohol-resistant once-a-day oral oxycodone formulation by its operating company IntelliPharmaCeutics Corp. of Toronto ("IntelliPharmaCeutics" or the "Company"). The product is covered by pending patent applications for its novel ReXista(TM) abuse and alcohol resistant drug delivery technology. It is one of the Company's line of in-house analgesic products in development for the management of moderate to severe chronic and acute pain.

The ReXista(TM) oxycodone product is a novel dosage form, designed to be resistant to abuse by oral ingestion when crushed or chewed, by injection when combined with solvents, and by nasal application when crushed or powdered. The abuse of this important pain relief drug has been well documented over many years.

The ReXista(TM) oxycodone product is also designed to resist release of the entire daily dose when consumed with alcohol in any quantity, a problem so serious with some opioid drugs such as hydromorphone that their use has been limited or curtailed by the FDA.

The product has been subjected to rigorous in-vitro testing and has met its design criteria for dissolution profiles and in-vitro resistance to simulated abuse. Based on these initial results, the product is expected to be effective for once-a-day dosing in the management of pain. It is also expected that it will resist abuse by oral, nasal or intravenous administration and resist unintended total dose release in the presence of alcohol.

The initial pilot clinical trial was designed to compare the pharmacokinetic characteristics of the IntelliPharmaCeutics ReXista(TM) oxycodone product, in a once-a-day 40mg dosage format, with a currently marketed branded oxycodone product, Purdue Pharma's Oxycontin(R), in a twice-a-day 20mg dosage format, under fasted
'/>"/>

SOURCE IntelliPharmaCeutics Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Your ... advances in modeling lithium-ion battery storage capacity. , ... from a theoretical model created at Lawrence ... that predicts how carbon components will perform ... storage emphasizes the urgent need for higher-performance batteries. ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
(Date:7/24/2014)... 2014  Spherix Incorporated (SPEX) -- an intellectual property ... intellectual property, today announced that the Company will issue ... 2014 on Monday, August 18, 2014 for shareholders. Management ... on Monday, August 18, 2014 to discuss the company,s ... CEO, Anthony Hayes . Following prepared ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2
... A. Knapp, 1, 2 E. Lehmann, 2 L. Hennes, 3 , ... , 1 Department of Biological Anthropology, University of Cambridge,U.K. ... of Wisconsin, , , ... Wisconsin Hospital and Clinics, Madison, Wisconsin, U.S.A. , ...
... , , Menu B. Leddy, Biotechnology Research Department,Orange ... , ... characterization of bacterial species from membrane , ... of bacterial cells from membrane biofilms cannot ...
... of Medical Microbiology and Hygiene,University of Regensburg, 93053 Regensburg, Germany , ... Abstract , Serodiagnosis of ... on the detection of antibodies to distinct EBV antigens. In the past few ... serodiagnostic assay systems , have been considerably ...
Cached Biology Technology:Separation of HLA-DRB Alleles by Denaturing Gradient Gel Electrophoresis using the DCode System 2Separation of HLA-DRB Alleles by Denaturing Gradient Gel Electrophoresis using the DCode System 3Separation of HLA-DRB Alleles by Denaturing Gradient Gel Electrophoresis using the DCode System 4Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 2Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 3Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 4Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 5Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 6Separation of 16S rRNA PCR Products From a Model Community Using Temporal Temperature Gradient Gel Electrophoresis, Rev A 7Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 2Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 3Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 4Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 5Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 6Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 7Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C 8
(Date:7/25/2014)... in the International Journal of Cancer earlier ... cancer based on findings showing successful reduction in the ... population of cells in the cervix. , The ... junction cells, or SCJ cells. These cells reside in ... origins of cervical cancer. A research team co-led by ...
(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
(Date:7/25/2014)... molecular testing panel developed at UPMC greatly increases ... for patients with thyroid nodules and cancer, report ... (UPCI), partner with UPMC CancerCenter., The test, available ... diagnostic testing agencies, improved the chances of patients ... according to the study published this month in ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... the tale of your family line. It carries the genetic ... a Tel Aviv University researcher, it,s also possible to use ... Eran Halperin of TAU,s Blavatnik School of Computer Science and ... of researchers from University of California, Los Angeles, are giving ...
... flock together and according to a new analysis so ... heritage of avian feather lice indicates that their louse ancestors first ... and then "radiated" to different habitats on those birds to ... species. This finding surprised the researchers because wing lice from many ...
... injured themselves during leisurely deep-sea diving trips and not from ... identified bone deformities on the fossilized remains of Ichthyosarians ... 245 million years ago. The lesions were similar ... in body pressure, and suggest the reptiles suffered from a ...
Cached Biology News:A GPS in your DNA 2Bird louse study shows how evolution sometimes repeats itself 2'Dinosaur bends' caused by prolonged diving 2
... Varioskan is a high performance ... dispenser and incubator. With the advanced ... and reliability for drug discovery assay ... for fluorescence intensity, time-resolved fluorescence and ...
Strip Removal Tool 25/Box...
Oven mesh sheets, large, 23 x 23cm, pack of 5...
... Lambda Protein Phosphatase ... Mn2+-dependent protein phosphatase with ... threonine and tyrosine residues. ... amino-acid product of the ...
Biology Products: